CoQ10 for Supplement Formulation: Ubiquinone vs Ubiquinol and How to Choose a Form
Coenzyme Q10 has been a staple of the supplement aisle for decades, which makes it easy to treat as a solved formulation problem. It is not. CoQ10 is a large, strongly lipophilic molecule that is practically insoluble in water, exists in two chemically distinct forms, and is offered in a wide range of physical presentations whose performance differs far more than their label names suggest.
For a formulator, three decisions determine whether the product works as intended and whether the specification holds up: which form, which physical presentation, and what the specification sheet actually commits to.
The two forms
Ubiquinone is the oxidised form, and it is the dominant form in most human tissue — the form the body works with after conversion. Commercially it is available in high-purity, well-characterised grades, and it is the volume mainstream of the category. As a dry powder it is relatively robust, provided it is protected from light and oxygen. Its market positioning is the standard form, carrying wide regulatory familiarity, and the formulation implication is that it suits cost-driven, high-volume programmes.
Ubiquinol is the reduced form. It is present in circulation, where its proportion changes with age, and it is available commercially — but at higher cost and with more demanding stabilisation requirements. It is markedly more oxidation-sensitive than ubiquinone, requiring careful protection and shorter handling windows, which is why it is positioned as a premium or specialised form. The formulation implication follows directly: a product built on ubiquinol needs a stability strategy designed for it from the start.
Two points follow from that comparison, and both are worth stating plainly.
First, the choice between the two forms is a commercial and stability decision before it is anything else. Ubiquinol oxidises to ubiquinone when poorly protected, so a formulation that specifies ubiquinol but does not control oxygen, light and heat may not be delivering meaningful quantities of ubiquinol at end of shelf life. Analytical verification of the reduced-form content at end of shelf life — not only at manufacture — is the control that matters.
Second, this article makes no claim about relative health effects. That is a clinical and regulatory question, it differs by market, and it belongs with your regulatory affairs team. The formulation question is separate: whichever form you choose, how do you deliver it intact?
The real problem is solubility
CoQ10’s low aqueous solubility is the primary obstacle to absorption and the reason the physical form of the raw material matters so much. Five presentations are commercially available, and they are not interchangeable.
Crystalline powder is standard CoQ10, supplied as a crystalline solid. It suits capsules and tablets at higher doses, and its limiting factor is dissolution — which makes crystal form and particle size the variables to control.
An oil suspension disperses CoQ10 in a vegetable oil and is designed for softgels and oil-based liquid fills. The considerations here are ease of dispersion and sedimentation behaviour, and it is worth verifying assay uniformity across the batch.
A water-soluble or self-emulsifying powder carries CoQ10 in a matrix that forms a fine emulsion on reconstitution. It is the presentation for sachets, stick packs, dry blends and instant beverages, and it is the practical route to a CoQ10 product that can be reconstituted in water.
A micellar or solubilised liquid presents CoQ10 in micellar form and is aimed at ready-to-drink beverages and liquid shots. The constraints are clarity, taste and physical stability through shelf life.
A beadlet or spray-dried dispersion carries CoQ10 in a protective matrix as discrete particles, for tablets, capsules and dry blends that need water dispersibility. Particle size, dispersibility and flowability are the items to specify.
The commercial insight here is straightforward: the growth formats for CoQ10 are sachets, sticks and beverages, and none of them can use crystalline powder. If your product roadmap includes any of those formats, the raw material specification has to be a dispersible one, and that decision should be made at the brief stage rather than after the artwork is designed.
Choosing by dosage form
For a hard capsule the recommended presentation is crystalline powder or beadlet, and the binding constraint is fill weight, since higher doses may force a large capsule or a multi-capsule dose. For a softgel it is an oil suspension, constrained by shell compatibility, the dose-to-volume ratio and migration over shelf life. For a tablet it is a compactable powder or beadlet, where the limits are compressibility at commercial speed and dose uniformity. For a sachet or stick pack it is a water-soluble or self-emulsifying powder, judged on reconstitution behaviour, taste and sedimentation in the glass. For a ready-to-drink beverage it is a micellar or solubilised liquid, where clarity, flavour masking and stability through pasteurisation set the boundaries. And for a gummy it is an emulsified or dispersible form, with the thermal load in the cook and the effects on colour and opacity as the constraints.
What to require on the specification
The specification is where this category is won or lost, because the difference between presentations is invisible on the label. Four groups of requirements carry the weight.
On identity and assay, the form must be declared explicitly as ubiquinone or ubiquinol; the assay must come from a validated method, typically HPLC, with the result basis stated; for ubiquinol the reduced-form content as a proportion of total CoQ10 must be given together with the analytical method used to distinguish the two forms; and trans-isomer content should be stated, given the isomer configuration of the molecule.
On physical and functional properties, the presentation type should be named along with the carrier or emulsifier system; powders and beadlets should carry a particle size distribution with its measurement method; dispersion or dissolution behaviour should be described in the intended application medium as a documented test rather than a claim; bulk density and flowability matter where the material runs on a high-speed tableting or filling line; and a colour-space reading belongs in the specification wherever appearance matters.
On safety and compliance, ask for a heavy metals panel with its method, plus a pesticide multiresidue screen where the material is plant- or fermentation-derived; a residual solvents statement against a recognised classification; a microbiological profile with limits for total plate count, yeast and mould, and the specified pathogens; allergen, GMO and radiation-treatment statements; and organic, Halal and Kosher certificates where claimed, with product-name scope.
On stability, require real-time retention data for assay and, for ubiquinol, for reduced-form content as well; physical stability data for liquid and dispersible systems covering colour, clarity and sedimentation; and the recommended packaging and storage conditions.
The item most often missing from CoQ10 specifications is physical stability data for dispersible and liquid systems. Chemical assay data is common; documented performance after twelve months in a sachet is not. Ask for it, and if it does not exist, build it into your own stability programme rather than discovering the problem at month nine.
Dosage and overage arithmetic
CoQ10 products are typically formulated in the 100–200 mg per day range in mature markets, with some products positioned at higher levels. Two arithmetic disciplines prevent label and specification disputes, and both belong in the brief rather than in the artwork review.
The first is to distinguish the form on the label basis. A specification written as “ubiquinol” is satisfied by fewer milligrams of the total CoQ10 than a specification written as “total CoQ10, of which ubiquinol.” Write the basis into the specification and the artwork brief simultaneously. The second is to build overage from measured data. Oxidative degradation means a formula that starts exactly at the target frequently finishes shelf life below it, so the overage should be derived from your own stability results at commercial packaging, not from a general rule.
Regulatory positioning: settle it before development
CoQ10 sits in different regulatory categories in different markets. In the United States, it is commonly sold as a dietary supplement ingredient, and permitted structure/function claims follow that framework. In the European Union, the health-claim regime is more restrictive, and several claims that are widely used elsewhere have not been authorised. Other markets vary further.
The practical implication for formulators: the permissible claim determines the acceptable dose, and the dose determines the format, and the format determines the raw material presentation. Running those four decisions in reverse order is the single most common cause of late reformulation in this category, and it is entirely avoidable by settling claim strategy first.
Cost per unit dose
As with other botanical specialties, price per kilogram is the wrong comparison. The figure that matters is cost per kilogram of material divided by active content, multiplied by the dose, multiplied by one plus the overage — written out, (cost per kg ÷ active content) × dose × (1 + overage).
To that you must add the format-specific costs that differ substantially between presentations: liquid filling versus powder blending, additional carrier declaration and label review, the stability programme, and — for some solubilised and micellar systems — licensing or trademark terms that constrain how the ingredient may be described.
Frequently Asked Questions
Which is better, ubiquinone or ubiquinol?
They are chemically distinct forms with different handling characteristics — ubiquinol is more oxidation-sensitive and requires a more deliberate protection strategy. Which is appropriate for a product is a claim, regulatory and cost decision for the brand owner. From a formulation standpoint, the question is whether the chosen form survives to end of shelf life, which is verified by measurement.
Can I use CoQ10 in a beverage?
Yes, but not as crystalline powder. You need a solubilised, micellar or water-dispersible presentation. The binding constraints are clarity, taste and stability through pasteurisation — all of which should be validated in your own process.
Why does my CoQ10 sachet not dissolve properly after storage?
Because the dispersion system has aged. Powders can cake, and the emulsifier matrix can change behaviour under humidity and temperature over time. Specify moisture content, require barrier packaging, and test reconstitution at end of shelf life rather than only on fresh material.
How do I verify ubiquinol content?
By requiring an analytical method that separates and quantifies the reduced and oxidised forms, and by requiring that result at end of shelf life rather than only at release. A total CoQ10 assay alone cannot distinguish the two.
What is the most common documentation gap?
Physical stability data for dispersible and liquid systems, and end-of-shelf-life data for reduced-form content. Both are inexpensive to obtain at the specification stage and expensive to discover later.
Formulate CoQ10 with DayNatural
DayNatural supplies water-soluble and standard-grade coenzyme Q10, alongside formulated powder systems for sachets, sticks and beverage applications. Every lot ships with analytical documentation covering assay, residual solvents, heavy metals and microbiological profile, with independent verification through our Mérieux NutriSciences testing programme.
